A discordant expression of these receptors and the primary tumor and corresponding metastases and/or CTCs has already been demonstrated with a discordance between primary BC and HER2 expression on CTCs in the setting of disease recurrence at variable rates, with a gain of HER2 from 9 % to over 60 % in different studies [32–39]. Here, ERBB2 is linked to breast cancer.